Early treatment: PreCISe-ly what the patient needs - PubMed

Early treatment: PreCISe-ly what the patient needs

Xavier Montalban. J Neurol Sci. 2009 Dec.

Abstract

Multiple sclerosis usually begins in young adulthood, and presents in 80-90% of patients with an initial disease course typified by relapses and remissions. The ability to recognise an individual's first neurological episode, commonly called a clinically isolated syndrome (CIS), represents a significant advance in the differential diagnosis of multiple sclerosis and offers the possibility of intervening at an earlier stage. Of note, over eighty percent of patients with a clinically isolated syndrome and magnetic resonance imaging lesions go on to develop multiple sclerosis within three years. The effect of first line therapies has been shown to be more pronounced when they are used at disease onset compared to a more advanced disease stage. First-line therapeutics have reached a milestone where a significant portion of disease activity is either preventable or at least modifiable. The results of the PreCISe Phase III multicentre, double-blind, randomised trial of glatiramer acetate versus placebo in patients with clinically isolated syndrome with abnormal MRI have recently been published. The study demonstrated a significant delay in progression to clinically definite multiple sclerosis in patients receiving glatiramer acetate, as well as a reduction in the burden of disease, as measured by both the number of new T2 lesions and T2 lesion volume. Considering these and previous results, this treatment should be regarded as an essential addition to the armamentarium of drugs available for the earliest treatment of this devastating disease.

Similar articles

• New options for early treatment of multiple sclerosis.

  Tintoré M. Tintoré M. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. J Neurol Sci. 2009. PMID: 19200870 Review.

• [Long-term effects of glatiramer acetate in multiple sclerosis].

  Brochet B. Brochet B. Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. Rev Neurol (Paris). 2008. PMID: 18790510 French.

• Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

  Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M. Comi G, et al. Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12. Mult Scler. 2013. PMID: 23234810 Clinical Trial.

• Management of worsening multiple sclerosis with mitoxantrone: a review.

  Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information